JMP Securities analyst Patrick Walravens downgrades Cloudera (NYSE:CLDR) from Outperform to Market Perform.
Credit Suisse Maintains Neutral on Quest Diagnostics, Lowers Price Target to $143
Credit Suisse analyst A.J. Rice maintains Quest Diagnostics (NYSE:DGX) with a Neutral and lowers the price target from $158 to $143.